Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07301008

Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US

Single-center, open label, prospective study conducted at Medstar Georgetown Headache Center. Men and woman ≥ 18 years old that are diagnosed with migraine with or without aura for at least 1 year, who report a reliable migraine trigger. Acceptable triggers for the study will include exercise, alcohol (less than one drink per day for woman and less than two drinks per day for men), air travel that lasts no more than 12 hours, sexual activity, fasting that lasts no more than 24 hours, stress or stress let-down headache.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

MedStar Health: Neurology at McLean

McLean, Virginia, 22101, United States

Location status: Recruiting

Location contact

Jessica Ailani, MD

PRINCIPAL_INVESTIGATOR

Yemisrach Tadesse

CONTACT

[email protected]

3015708508

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with at least 1 year history of episodic migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders-3 (ICHD-3)
  • Men and women ≥ 18 years old .
  • Average of 2-8 migraine attacks of moderate or severe intensity per month within the last 3 months prior to the screening visit
  • Headache/migraine onset before age 50 years
  • Migraine attacks, on average, lasting 4-72 hours if untreated
  • At least 48 hours between migraine attacks
  • Ability to distinguish migraine attacks from tension or cluster headaches
  • Particpants on SOC treatment should be on stable regimen for at least 3 months prior to enrollment and should not change their regimen during the course of the study
  • Participant may have been on treatment with Botox or mAbs for the last 6 months
  • Participants experience migraine ≥75% of the time following exposure to a trigger during the run-in period. Acceptable triggers include exercise, alcohol ( less than one drink per day for woman and less than two drinks per day for men), air travel that lasts no more than 12 hours, sexual activity, fasting that lasts no more than 24 hours, stress or weekend/ let-down

Exclusion criteria

  • Using gepants as preventive treatment (atogepant once daily (QD) or rimegepant every other day (EOD)), or using zavegepant or ubrogepant as an acute treatment
  • History of use of narcotic or barbiturate containing medications, including opioids (e.g., morphine, codeine, oxycodone, and hydrocodone) on ≥5 days per month on a regular basis for ≥3 months prior to screening
  • Current evidence of uncontrolled, unstable, or recently diagnosed cardiovascular disease, uncontrolled hypertension, or uncontrolled diabetes.
  • Current diagnosis of major depressive disorder requiring treatment with atypical antipsychotics, schizophrenia, bipolar disorder, or borderline personality disorder.
  • Women must not be pregnant, lactating or breastfeeding

Treatment and study plan

Rimegepant 75 MG

Drug

The interventional product is rimegepant ODT 75 mg. Rimegepant 75mg ODT will be given 2 hours prior to a trigger exposure for exercise, alcohol (less than one drink per day for woman and less than two drinks per day for men), air travel that lasts no more than 12 hours, sexual activity, fasting that lasts no more than 24 hours rimegepant will be dosed 2 hours prior to trigger exposure. For weekend or let down headache and changes in sleep pattern, rimegepant will be dosed the night before. The maximum dose in a 24-hour period is 75mg.

Primary outcomes

  1. Percentage of preemptive treatments with rimegepant in which migraine with a moderate to severe headache intensity

    Time frame: 24 hour post dose

    Percentage of preemptive treatments with rimegepant in which migraine with a moderate to severe headache intensity occurs within 24 hours

Secondary outcomes

  1. Percentage of preemptive treatments with rimegepant

    Time frame: 24 hour, 48 hour post dose

    Percentage of preemptive treatments with rimegepant in which migraine occurs within 24 hours

    • Percentage of preemptive treatments with rimegepant that require rescue medication within 24 hours
    • Percentage of preemptive treatments with rimegepant that result in acute medication use within 48 hours of treatment
  2. Patient satisfaction with preemptive treatment with rimegepant

    Time frame: At the end of the study completion( 2 month after enrollment)

    Patient satisfaction with preemptive rimegepant treatment will be assessed in the case report form using a Likert scale

  3. The effect of preemptive treatment with rimegepant on Patient Global Impression of Change (PGIC)

    Time frame: At the end of study completion( 2 months after enrollement)

    The effect of preemptive treatment with rimegepant on Patient Global Impression of Change (PGIC) using a graded scale of 1-7.

Study contacts

Contact information is provided by the study sponsor or research team.

Yemisrach Tadesse

CONTACT

[email protected]

3015708508

Sponsors and collaborators

Lead sponsor

Medstar Health Research Institute

Other

Collaborators

  • Pfizer

Registry information

Acronym: RIM

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Dec 24, 2025
Registry last updated
Dec 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.